Clinical Trial Detail

NCT ID NCT03245151
Title Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eisai Inc.
Indications

rhabdomyosarcoma

Advanced Solid Tumor

malignant glioma

Ewing sarcoma

Therapies

Everolimus + Lenvatinib

Age Groups: adult child

No variant requirements are available.